<DOC>
	<DOCNO>NCT00731237</DOCNO>
	<brief_summary>This trial ass physician-determined XIENCE V® EECSS acute performance , deliverability resource utilization catheterization lab commercial use various physician range coronary stenting experience</brief_summary>
	<brief_title>XIENCE V® EXCEED : Evaluation XIENCE V® Catheterization Lab Endpoints Excellence Delivery</brief_title>
	<detailed_description>This study evaluate overall physician-determined XIENCE V® Everolimus Eluting Coronary Stent system ( XIENCE V® ) acute performance , deliverability resource utilization catheterization lab `` real world '' use broad group physician variety health care facility . This study include consecutively enrolled patient United States America ( USA ) consent participate receive XIENCE V® stent .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General The patient agree participate study sign IRB approve informed consent form prior index procedure . Alternatively , patient 's legally authorize representative agrees patient 's participation study sign inform consent form prior index procedure . General Inability obtain informed consent exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Drug Eluting Stent</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Everolimus</keyword>
</DOC>